Log In
BCIQ
Print this Print this
 

HORA-RPE65

  Manage Alerts
Collapse Summary General Information
Company Horama S.A.S.
DescriptionSerotype 4 rAAV that delivers the gene for RPE65
Molecular Target Retinal pigment epithelium-specific protein 65kDa (RPE65)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPhase I/II
Standard IndicationBlindness
Indication DetailsTreat Leber's congenital amaurosis (LCA)
Regulatory Designation EU - Orphan Drug (Treat Leber's congenital amaurosis (LCA))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today